You have accessJournal of UrologyBladder Cancer: Epidemiology & Evaluation III1 Apr 2017PD57-07 RACE AND FINASTERIDE USE: DIFFERENTIAL IMPACT ON BLADDER CANCER RISK Abhishek Srivastava, Ethan Fram, Ilir Agalliu, Mark Schoenberg, and Alexander Sankin Abhishek SrivastavaAbhishek Srivastava More articles by this author , Ethan FramEthan Fram More articles by this author , Ilir AgalliuIlir Agalliu More articles by this author , Mark SchoenbergMark Schoenberg More articles by this author , and Alexander SankinAlexander Sankin More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2017.02.2609AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES A recent subset analysis of the Prostate, Lung, Colorectal, and Ovarian cancer (PLCO) study has suggested that Finasteride use was associated with a reduced incidence of bladder cancer (HR=0.634, 95% confidence interval=0.493-0.816; p = 0.0004). We sought to validate this finding in a multiracial population in our tertiary care center. METHODS We identified patients in our institutional database with Benign Prostatic Hyperplasia (BPH) based on International Classification of Diseases (ICD) 9 and 10 codes assigned between 2000 and 2016. From this cohort we then identified patients who were on Finasteride and those that developed bladder cancer. All demographic and clinical variables including age, race, smoking history, finasteride use were collected via an institutional database that prospectively extracts data from electronic medical records (EMR). Finasteride use was based on the documented prescriptions. Chi-square test was used to compare the proportion of bladder cancer patients between two groups (i.e. users and non-users of Finasteride). Multivariate logistic regression analysis was performed to determine the association of finasteride use and diagnosis of bladder cancer controlling for age, smoking history and race. RESULTS We identified 42,774 patients with BPH. The median follow-up was 87 months. There were 11,864 (27.7%) African Americans (AA), 11,863 (27.7%) Caucasians, and 6,340 (14.8%) Hispanics in this population. 5,698 (13.3%) patients were prescribed Finasteride. Bladder cancer was diagnosed in 84 of 5,698 (1.5%) patients who were prescribed Finasteride compared with 863 of 37,076 (2.3%), who were not prescribed Finasteride (p<0.001). Multivariate logistic regression analysis showed that Finasteride use was protective of bladder cancer (OR: 0.57, CI: 0.45-0.71, p<0.001). When we stratified the data based on race, Finasteride use was protective of bladder cancer in Caucasians (2.1% vs. 3.8%, p=0.001) and Hispanics (0.8% vs. 1.6%, p=0.042), but not in AA (1.7% vs. 1.7%, p=0.854). CONCLUSIONS Our study confirms previous findings from the PLCO study that men who are on Finasteride have lower incidence of bladder cancer but only in Caucasians and Hispanics. Future research and randomized controlled studies may be needed to confirm these findings. © 2017FiguresReferencesRelatedDetails Volume 197Issue 4SApril 2017Page: e1123-e1124 Advertisement Copyright & Permissions© 2017MetricsAuthor Information Abhishek Srivastava More articles by this author Ethan Fram More articles by this author Ilir Agalliu More articles by this author Mark Schoenberg More articles by this author Alexander Sankin More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...